Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) CEO Christopher Gibson sold 40,000 shares of the company's stock in a transaction on Wednesday, April 3rd. The shares were sold at an average price of $8.84, for a total transaction of $353,600.00. Following the completion of the sale, the chief executive officer now owns 978,524 shares of the company's stock, valued at approximately $8,650,152.16. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Christopher Gibson also recently made the following trade(s):
- On Thursday, March 28th, Christopher Gibson sold 40,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $10.10, for a total value of $404,000.00.
- On Wednesday, March 6th, Christopher Gibson sold 36,319 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $11.86, for a total value of $430,743.34.
- On Wednesday, February 7th, Christopher Gibson sold 48,272 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $9.22, for a total transaction of $445,067.84.
Recursion Pharmaceuticals Stock Up 1.6 %
Have You Seen Elon’s New A.I. Device? (Picture Inside)
From InvestorPlace | Ad
A strange new era for mankind is upon us...
And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day.
Elon believes A.I. is advancing so fast...
This strange new device to protect us against that A.I. threat...
Shares of NASDAQ RXRX opened at $8.87 on Friday. The stock's 50 day moving average price is $11.03 and its 200-day moving average price is $9.07. The company has a market capitalization of $2.08 billion, a PE ratio of -5.72 and a beta of 0.76. Recursion Pharmaceuticals, Inc. has a twelve month low of $4.54 and a twelve month high of $16.75.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its quarterly earnings results on Tuesday, February 27th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.46) by $0.06. Recursion Pharmaceuticals had a negative net margin of 735.99% and a negative return on equity of 72.88%. The company had revenue of $10.89 million during the quarter, compared to analyst estimates of $12.37 million. As a group, research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.63 EPS for the current fiscal year.
Institutional Investors Weigh In On Recursion Pharmaceuticals
Several institutional investors have recently made changes to their positions in the stock. ARK Investment Management LLC increased its holdings in shares of Recursion Pharmaceuticals by 200.4% in the fourth quarter. ARK Investment Management LLC now owns 20,654,287 shares of the company's stock worth $203,651,000 after purchasing an additional 13,777,689 shares during the period. Mubadala Investment Co PJSC bought a new stake in Recursion Pharmaceuticals in the 4th quarter worth approximately $128,041,000. Nvidia Corp bought a new stake in shares of Recursion Pharmaceuticals in the 4th quarter worth approximately $75,985,000. FMR LLC boosted its position in Recursion Pharmaceuticals by 134.4% during the third quarter. FMR LLC now owns 10,689,532 shares of the company's stock valued at $81,775,000 after buying an additional 6,129,935 shares during the period. Finally, Sumitomo Mitsui Trust Holdings Inc. boosted its holdings in Recursion Pharmaceuticals by 161.2% during the 4th quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 9,203,780 shares of the company's stock valued at $90,749,000 after acquiring an additional 5,680,656 shares during the period. Hedge funds and other institutional investors own 89.06% of the company's stock.
Analyst Upgrades and Downgrades
A number of equities analysts have commented on RXRX shares. TD Cowen initiated coverage on Recursion Pharmaceuticals in a research note on Friday, January 26th. They set a "market perform" rating on the stock. KeyCorp boosted their price objective on shares of Recursion Pharmaceuticals from $15.00 to $16.00 and gave the stock an "overweight" rating in a research note on Monday, March 4th. Finally, Needham & Company LLC increased their price objective on shares of Recursion Pharmaceuticals from $15.00 to $17.00 and gave the stock a "buy" rating in a research report on Wednesday, February 28th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $12.75.
Check Out Our Latest Research Report on RXRX
Recursion Pharmaceuticals Company Profile
(
Get Free Report)
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
